Rinatine Mpa Tablet 25/5 mg (Empagliflozin, Linagliptin)
Empagliflozin 25mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
MFDS item code 202502794 · Approved 2025.10.29
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medicine is used to assist dietary and exercise therapy in controlling blood sugar in patients with type 2 diabetes. The ingredients empagliflozin and linagliptin work together to effectively help manage blood sugar levels. Therefore, taking this medicine can improve blood sugar management and contribute to the treatment of diabetes.
The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. If additional glycemic control is needed in patients who tolerate empagliflozin 10 mg/linagliptin 5 mg, the dose of this medicine may be increased to 25/5 mg once daily. Patients switching to this medicine from combination therapy with empagliflozin and linagliptin should receive the same doses they were taking previously. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Patients with renal impairment This medicine is not recommended for patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 for the purpose of improving glycemic control. No dose adjustment is necessary in patients with an eGFR of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. Elderly patients No dose adjustment is necessary based on age. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medicine consists of two ingredients, empagliflozin and linagliptin, and is primarily used for the treatment of type 2 diabetes. First, it should not be used by individuals who are allergic to empagliflozin, linagliptin, or any other ingredients in this medicine. It is also not to be administered to patients with type 1 diabetes, diabetic ketoacidosis, or those undergoing dialysis. Second, patients with impaired kidney function should regularly undergo kidney function tests prior to using this medicine, and exercise caution if taking other medications that may affect kidney function. Caution is also necessary for patients with heart failure, and if symptoms of acute pancreatitis occur, the medication should be stopped immediately. Additionally, if symptoms resembling blistering disorders like bullous pemphigoid appear on the skin, consult a doctor immediately. Third, when taking this medicine, side effects such as urinary tract infections, genital infections, hypoglycemia, dehydration, and low blood pressure may occur, so be vigilant for symptoms. Particularly, if taking sulfonylureas or insulin together, the risk of hypoglycemia may increase, so blood sugar levels should be closely monitored. Fourth, dizziness or low blood pressure due to fluid volume loss may occur, so elderly individuals or those with low blood pressure should take extra caution, and if dehydration symptoms occur, the use of this medicine may be temporarily halted. Fifth, this medicine is not recommended for women who are pregnant or breastfeeding, and consultation with a doctor is essential if planning for pregnancy or if already pregnant. Sixth, this medicine has not been confirmed for safety and efficacy in children under the age of 18, and its use is not recommended. Finally, taking this medicine may involve risks during driving or operating machinery due to hypoglycemia, so caution is necessary. Before and during the use of this medicine, discuss thoroughly with your physician, and report any unusual symptoms to healthcare personnel immediately.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage will help preserve the drug's effectiveness and safety for a long time.
Pink round film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 5mg · Empagliflozin 25mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Green Cross
CombinationLinagliptin Micronized 5mg · Empagliflozin 10mg
Tablet · Prescription medication · Combination
Green Cross Corporation
CombinationEmpagliflozin 10mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Empagliflozin 10mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Cheil Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.